The Japanese journal of surgery

, Volume 21, Issue 5, pp 590–593 | Cite as

Clinical significance of P-glycoprotein expression analyzed by immunohistochemical staining in cancer tissues

  • Ryungsa Kim
  • Naoki Hirabayashi
  • Masahiko Nishiyama
  • Kenjiro Aogi
  • Tetsuya Toge
Short Communications


P-glycoprotein is a transmembrane protein with increased drug efflux from resistant cells, which is encoded by the MDR1 gene. An overexpression of P-glycoprotein has been reported to correlate with the degree of resistance to anticancer agents, especially to adriamycin. In this study, the expression of P-glycoprotein was analyzed immunohistochemically by using a monoclonal antibody, MRK16 against P-glycoprotein in 18 fresh human tumors. The expression of P-glycoprotein was detected in eight (44 per cent) tumor specimens out of 18 patients. Although six (75.0 per cent) of the 8 P-glycoprotein positive tumors were resistant to adriamycin, the other two tumors showed clinical responses. Furthermore, five (50.0 per cent) of the 10 P-glycoprotein negative tumors exhibited positive clinical responses. These results suggest that P-glycoprotein expression may not be a useful marker to predict intrinsic resistance to adriamycin in fresh human tumors.

Key Words

P-glycoprotein monoclonal antibody adriamycin resistance multidrug resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 1986; 5: 24–46.Google Scholar
  2. 2.
    Pastan I, Gottesman MM. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316; 1388–1393.PubMedCrossRefGoogle Scholar
  3. 3.
    Bhalla K, Hindenberg A, Taub RN, Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res 1985; 45: 3657–3662.PubMedGoogle Scholar
  4. 4.
    Fojo A, Akiyama S, Gottesman MM, Pastan I. Reduced drug accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res 1985; 45: 3002–3007.PubMedGoogle Scholar
  5. 5.
    Croop JM, Gros P, Housman DE. Genetics of multidrug resistance. J Clin Invest 1988; 81: 1303–1309.PubMedCrossRefGoogle Scholar
  6. 6.
    Hamada H, Tsuruo T. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci 1986: 83: 7785–7789.PubMedCrossRefGoogle Scholar
  7. 7.
    Hsu SM, Raine L, Fanger H. Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabelled antibody (PAP) procedure. J Histochem Cytochem 1981; 29: 579–580.Google Scholar
  8. 8.
    Koyama M. Criteria of Japan Society for Cancer Therapy. Jpn J Cancer Chemotherapy 1986; 13: 391–396 (in Japanese)Google Scholar
  9. 9.
    Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985; 3: 311–315.PubMedGoogle Scholar
  10. 10.
    Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987; 5: 1452–1460.PubMedGoogle Scholar
  11. 11.
    Ma DDF, Davey RA, Harman DH, Isbister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR. Detection of a multidrug resistant phenotype in acute nonlymphoblastic leukemia. Lancet 1987; 1: 135–137.PubMedCrossRefGoogle Scholar
  12. 12.
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrugresistant gene in human tumors and tissues. Proc Natl Acad Sci 1987; 84: 265–269.PubMedCrossRefGoogle Scholar
  13. 13.
    Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistancein vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989; 81: 696–701.PubMedGoogle Scholar
  14. 14.
    Batist G, Tulpule A, Shinha BK, Katki AG, Meyers CH, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells. J Biol Chem 1986; 261: 15544–15549.PubMedGoogle Scholar
  15. 15.
    Yin MB, Bankusli I, Rustum YM. Mechanism of thein vivo resistance to adriamycin and modulation by calcium channel blockers in mice. Cancer Res 1989; 49: 4729–4733.PubMedGoogle Scholar
  16. 16.
    Furguson PJ, Fisher MH, Stephenson J, Li D, Zhou B, Cheng Y. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 1988; 48: 5956–5964.Google Scholar

Copyright information

© The Japan Surgical Society 1991

Authors and Affiliations

  • Ryungsa Kim
    • 1
  • Naoki Hirabayashi
    • 1
  • Masahiko Nishiyama
    • 1
  • Kenjiro Aogi
    • 1
  • Tetsuya Toge
    • 1
  1. 1.The Department of Surgery, Research Institute for Nuclear Medicine and BiologyHiroshima UniversityHiroshimaJapan

Personalised recommendations